123 related articles for article (PubMed ID: 35818232)
21. Cost-effectiveness analysis in the Spanish setting of the PEAK trial of panitumumab plus mFOLFOX6 compared with bevacizumab plus mFOLFOX6 for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Rivera F; Valladares M; Gea S; López-Martínez N
J Med Econ; 2017 Jun; 20(6):574-584. PubMed ID: 28107090
[TBL] [Abstract][Full Text] [Related]
22. Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature.
de Andrade DP; Lima JP; Lima AD; Sasse AD; dos Santos LV
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S15-7. PubMed ID: 21768792
[TBL] [Abstract][Full Text] [Related]
23. [Investigation of FOLFIRI/FOLFOX (+/-bevacizumab) therapy for patients with metastatic colorectal cancer in our hospital].
Hosoda K; Aoki M; Kido H; Natsu K; Tamura H; Kojima M; Amemiya T; Kamoshida T
Gan To Kagaku Ryoho; 2010 May; 37(5):841-5. PubMed ID: 20495313
[TBL] [Abstract][Full Text] [Related]
24. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
[TBL] [Abstract][Full Text] [Related]
25. A phase I/II, open-label, randomised study of nintedanib plus mFOLFOX6 versus bevacizumab plus mFOLFOX6 in first-line metastatic colorectal cancer patients.
Van Cutsem E; Prenen H; D'Haens G; Bennouna J; Carrato A; Ducreux M; Bouché O; Sobrero A; Latini L; Staines H; Oum'Hamed Z; Dressler H; Studeny M; Capdevila J
Ann Oncol; 2015 Oct; 26(10):2085-91. PubMed ID: 26272806
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II open-label study of mFOLFOX6 in combination with linifanib or bevacizumab for metastatic colorectal cancer.
O'Neil BH; Cainap C; Van Cutsem E; Gorbunova V; Karapetis CS; Berlin J; Goldberg RM; Qin Q; Qian J; Ricker JL; Fischer J; McKee MD; Carlson DM; Kim TW
Clin Colorectal Cancer; 2014 Sep; 13(3):156-163.e2. PubMed ID: 25066269
[TBL] [Abstract][Full Text] [Related]
27. AtezoTRIBE: a randomised phase II study of FOLFOXIRI plus bevacizumab alone or in combination with atezolizumab as initial therapy for patients with unresectable metastatic colorectal cancer.
Antoniotti C; Borelli B; Rossini D; Pietrantonio F; Morano F; Salvatore L; Lonardi S; Marmorino F; Tamberi S; Corallo S; Tortora G; Bergamo F; Brunella DS; Boccaccino A; Grassi E; Racca P; Tamburini E; Aprile G; Moretto R; Boni L; Falcone A; Cremolini C
BMC Cancer; 2020 Jul; 20(1):683. PubMed ID: 32698790
[TBL] [Abstract][Full Text] [Related]
28. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Müller CI; Schulmann K; Reinacher-Schick A; Andre N; Arnold D; Tannapfel A; Arkenau H; Hahn SA; Schmoll SH; Porschen R; Schmiegel W; Graeven U;
Int J Colorectal Dis; 2008 Nov; 23(11):1033-9. PubMed ID: 18594845
[TBL] [Abstract][Full Text] [Related]
29. [Effect of Shenqi Fuzheng injection combined with chemotherapy in treating advanced colorectal carcinoma].
Liang QL; Pan DC; Xie JR
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 May; 29(5):439-41. PubMed ID: 19673337
[TBL] [Abstract][Full Text] [Related]
30. Significance of KRAS mutation in patients receiving mFOLFOX6 with or without bevacizumab for metastatic colorectal cancer.
Koike J; Ushigome M; Funahashi K; Shiokawa H; Kaneko T; Arai K; Matsuda S; Kagami S; Suzuki T; Kurihara A; Shimada H; Kaneko H
Hepatogastroenterology; 2014; 61(136):2222-6. PubMed ID: 25699356
[TBL] [Abstract][Full Text] [Related]
31. [Effect of withdrawal of 5-fluorouracil bolus administration on recovery from neutropenia in colorectal cancer patients treated with mFOLFOX6 chemotherapy-comparison with total dosage reduction].
Ueda H; Demizu M; Oosawa M; Chihara S; Nakanishi Y; Maeda C; Yano K; Kimura F; Iwakawa S
Gan To Kagaku Ryoho; 2009 May; 36(5):789-93. PubMed ID: 19461179
[TBL] [Abstract][Full Text] [Related]
32. BRAF-Mutated Colorectal Cancer Exhibits Distinct Clinicopathological Features from Wild-Type BRAF-Expressing Cancer Independent of the Microsatellite Instability Status.
Jang MH; Kim S; Hwang DY; Kim WY; Lim SD; Kim WS; Hwang TS; Han HS
J Korean Med Sci; 2017 Jan; 32(1):38-46. PubMed ID: 27914130
[TBL] [Abstract][Full Text] [Related]
33. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer.
André T; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt C; Smith D; Garcia-Carbonero R; Benavides M; Gibbs P; de la Fouchardiere C; Rivera F; Elez E; Bendell J; Le DT; Yoshino T; Van Cutsem E; Yang P; Farooqui MZH; Marinello P; Diaz LA;
N Engl J Med; 2020 Dec; 383(23):2207-2218. PubMed ID: 33264544
[TBL] [Abstract][Full Text] [Related]
34. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801).
Nakayama G; Uehara K; Ishigure K; Yokoyama H; Ishiyama A; Eguchi T; Tsuboi K; Ohashi N; Fujii T; Sugimoto H; Koike M; Fujiwara M; Ando Y; Kodera Y
Cancer Chemother Pharmacol; 2012 Oct; 70(4):575-81. PubMed ID: 22886005
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and toxicity of fluorouracil, leucovorin plus oxaliplatin (FOLFOX4 and modified FOLFOX6) followed by fluorouracil, leucovorin plus irinotecan(FOLFIRI)for advanced or metastatic colorectal cancer--case studies.
Ohtani H; Arimoto Y; Nishio K; Kanamiya Y; Oba H; Adachi K; Shintani M; Nakamura R; Yui S
Gan To Kagaku Ryoho; 2008 Oct; 35(10):1769-74. PubMed ID: 18931586
[TBL] [Abstract][Full Text] [Related]
36. [Lynch syndrome and microsatellite instability: a review].
Desselle F; Verset G; Polus M; Louis E; Van Daele D
Rev Med Liege; 2012 Dec; 67(12):638-43. PubMed ID: 23342874
[TBL] [Abstract][Full Text] [Related]
37. The Impact of Mismatch Repair Status in Colorectal Cancer on the Decision to Treat With Adjuvant Chemotherapy: An Australian Population-Based Multicenter Study.
He EY; Hawkins NJ; Mak G; Roncolato F; Goldstein D; Liauw W; Clingan P; Chin M; Ward RL
Oncologist; 2016 May; 21(5):618-25. PubMed ID: 27009937
[TBL] [Abstract][Full Text] [Related]
38. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
39. [Efficacy and safety of modified FOLFOX6 regimen in aged patients with nonresectable colorectal cancer].
Ishiguro T; Ishibashi K; Okada N; Kuwabara K; Miyazaki T; Yokoyama M; Matsuki M; Sano M; Inoue N; Ishida H
Gan To Kagaku Ryoho; 2008 Nov; 35(12):2286-8. PubMed ID: 19106598
[TBL] [Abstract][Full Text] [Related]
40. A phase I trial of everolimus in combination with 5-FU/LV, mFOLFOX6 and mFOLFOX6 plus panitumumab in patients with refractory solid tumors.
McRee AJ; Davies JM; Sanoff HG; Goldberg RM; Bernard S; Dees EC; Keller K; Ivanova A; O'Neil BH
Cancer Chemother Pharmacol; 2014 Jul; 74(1):117-23. PubMed ID: 24819684
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
